Form 4: Biogen Executive Susan Alexander Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Legal Officer of Biogen, Susan Alexander, reports the vesting and disposal of restricted stock units and common stock.
Summary
- Susan Alexander, EVP and Chief Legal Officer of Biogen, filed a Form 4 detailing changes in beneficial ownership.
- On February 10, 2025, 2,575 restricted stock units vested and were converted into common stock.
- Ms. Alexander disposed of 807 shares of common stock at a price of $142.54.
- Following these transactions, Ms. Alexander directly owns 36,265 shares of Biogen common stock.
- Ms. Alexander indirectly owns 20,082 shares through the Susan H. Alexander 2021 Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the trading activities of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
- The transactions are part of the executive's compensation and benefits package.
Key Dates
| Date | Description |
|---|---|
| 02/10/2022 | Grant date of restricted stock units, vesting in three equal yearly installments beginning on the first anniversary. |
| 02/10/2025 | Date of transaction: vesting of restricted stock units and disposal of common stock. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.